MA41790B1 - Dérivé de morphinane - Google Patents
Dérivé de morphinaneInfo
- Publication number
- MA41790B1 MA41790B1 MA41790A MA41790A MA41790B1 MA 41790 B1 MA41790 B1 MA 41790B1 MA 41790 A MA41790 A MA 41790A MA 41790 A MA41790 A MA 41790A MA 41790 B1 MA41790 B1 MA 41790B1
- Authority
- MA
- Morocco
- Prior art keywords
- represent hydrogen
- ring
- atoms
- carbon atoms
- carbon atom
- Prior art date
Links
- 150000003809 morphinane derivatives Chemical class 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Dérivé de morphinane représenté par la formule générale (i) suivante : (où r1 représente l'hydrogène, un alkyle en c1-10, un cycloalkylalkyle où le fragment cycloalkyle a 3 à 6 atomes de carbone, et le fragment alkylène a 1 à 5 atomes de carbone, etc.,r2 représente cycle hétérocyclique contenant 1 à 4 hétéroatomes choisis parmi n, o et s et au moins un atome de carbone en tant qu'atomes constituant le cycle, contenant au moins un ensemble d'atomes constituant le cycle adjacents liés par une double liaison, et en outre substitué par au moins un groupe oxo,y se lie à un atome de carbone en tant qu'atome constituant le cycle de r2, r3, r4 et r5 représentent l'hydrogène ; hydroxy, etc., r6a et r6bre représentent l'hydrogène, etc., r7 et r8 représentent l'hydrogène, etc., r9 et r10, qui sont identiques ou différents, représentent l'hydrogène, etc.,x représente o ou ch2, ety représente c(=o)),un tautomère ou stéréoisomère du composé, ou un sel pharmaceutiquement acceptable de celui-ci, ou un solvate de celui-ci est utilisé comme anxiolytique médicament, antidépresseur, etc
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015054079 | 2015-03-17 | ||
| PCT/JP2016/058475 WO2016148232A1 (fr) | 2015-03-17 | 2016-03-17 | Dérivé de morphinane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41790A MA41790A (fr) | 2021-06-02 |
| MA41790B1 true MA41790B1 (fr) | 2022-02-28 |
Family
ID=56919074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41790A MA41790B1 (fr) | 2015-03-17 | 2016-03-17 | Dérivé de morphinane |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10442802B2 (fr) |
| EP (2) | EP3272750B1 (fr) |
| JP (5) | JP6692345B2 (fr) |
| KR (2) | KR102813010B1 (fr) |
| CN (3) | CN107614500B (fr) |
| AU (2) | AU2016234222C1 (fr) |
| BR (1) | BR112017019805B1 (fr) |
| CA (1) | CA2979023C (fr) |
| CY (1) | CY1124908T1 (fr) |
| DK (1) | DK3272750T3 (fr) |
| ES (1) | ES2904511T3 (fr) |
| HU (1) | HUE057266T2 (fr) |
| IL (1) | IL254473B (fr) |
| MA (1) | MA41790B1 (fr) |
| MX (2) | MX384744B (fr) |
| MY (1) | MY197742A (fr) |
| PH (1) | PH12017501655B1 (fr) |
| PL (1) | PL3272750T3 (fr) |
| RU (1) | RU2762567C2 (fr) |
| SG (2) | SG11201707427TA (fr) |
| TW (2) | TWI778933B (fr) |
| WO (1) | WO2016148232A1 (fr) |
| ZA (1) | ZA201706882B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2979023C (fr) * | 2015-03-17 | 2023-09-26 | University Of Tsukuba | Derive de morphinane |
| US20210371422A1 (en) | 2016-08-09 | 2021-12-02 | Nippon Chemiphar Co., Ltd. | Morphinan derivative |
| CN117122598A (zh) * | 2016-09-16 | 2023-11-28 | 日本化学药品株式会社 | 吗啡喃衍生物的在阿片δ受体激动剂相关疾病的治疗中的应用 |
| WO2018066532A1 (fr) * | 2016-10-03 | 2018-04-12 | 学校法人 星薬科大学 | Composition pharmaceutique contenant un dérivé de morphinane et son utilisation en tant qu'analgésique |
| US20220289748A1 (en) | 2019-07-19 | 2022-09-15 | Nippon Chemiphar Co., Ltd. | Method for producing phenol derivative |
| EP3984982A4 (fr) | 2019-07-19 | 2023-01-18 | Nippon Chemiphar Co., Ltd. | Procédé de production d'un dérivé de morphinane |
| AU2021332768B2 (en) | 2020-08-28 | 2024-04-18 | Nippon Chemiphar Co., Ltd. | Method for preparing morphinan derivative having diaryl ether skeleton using novel copper catalyst |
| MX2023009942A (es) * | 2021-02-26 | 2023-10-19 | Univ Tokyo Science Found | Composicion farmaceutica para el tratamiento o la prevencion de trastornos relacionados con el estres. |
| CN116997360A (zh) * | 2021-02-26 | 2023-11-03 | 学校法人东京理科大学 | 应激相关障碍的治疗或预防用医药组合物 |
| TW202547487A (zh) * | 2024-03-18 | 2025-12-16 | 學校法人東京理科大學 | 失樂症的治療或預防用醫藥組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005231995A (ja) | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物 |
| DE10161963A1 (de) * | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung |
| AR044010A1 (es) | 2003-04-11 | 2005-08-24 | Janssen Pharmaceutica Nv | Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica |
| WO2006107254A1 (fr) | 2005-04-04 | 2006-10-12 | Astrazeneca Ab | Nouveaux diazaspiroalcanes et leur application au traitement de maladies faisant intervenir ccr8 |
| JPWO2008001859A1 (ja) | 2006-06-30 | 2009-11-26 | 学校法人北里研究所 | オピオイドδ受容体アゴニスト |
| CN101918403A (zh) | 2007-09-06 | 2010-12-15 | 阵列生物制药公司 | 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物 |
| AU2010313392B2 (en) | 2009-10-30 | 2015-07-09 | Janssen Pharmaceutica Nv | Pyrazines as delta opioid receptor modulators |
| EP2525659B1 (fr) | 2010-01-19 | 2019-02-27 | Merck Sharp & Dohme Corp. | COMPOSÉS PYRAZOLO[1,5-a]PYRIMIDINES EN TANT QU'INHIBITEURS DE mTOR |
| ES2604931T3 (es) | 2010-12-23 | 2017-03-10 | Phoenix Pharmalabs, Inc. | Nuevos morfinanos útiles como analgésicos |
| JP2014073964A (ja) | 2011-01-28 | 2014-04-24 | Kitasato Institute | モルヒナン誘導体 |
| HUE032470T2 (en) | 2011-09-09 | 2017-09-28 | The Kitasato Inst | Morphinan derivative |
| WO2014021273A1 (fr) * | 2012-07-30 | 2014-02-06 | 学校法人北里研究所 | Dérivés morphinane |
| EP2931725B1 (fr) | 2012-12-14 | 2017-02-15 | Purdue Pharma LP | Dérivés de morphinane contenant de l'azote et leur utilisation |
| CA2908805A1 (fr) | 2013-03-08 | 2014-09-12 | The Kitasato Institute | Derive de morphinane |
| CA2979023C (fr) * | 2015-03-17 | 2023-09-26 | University Of Tsukuba | Derive de morphinane |
| CN117122598A (zh) | 2016-09-16 | 2023-11-28 | 日本化学药品株式会社 | 吗啡喃衍生物的在阿片δ受体激动剂相关疾病的治疗中的应用 |
-
2016
- 2016-03-17 CA CA2979023A patent/CA2979023C/fr active Active
- 2016-03-17 ES ES16765061T patent/ES2904511T3/es active Active
- 2016-03-17 EP EP16765061.3A patent/EP3272750B1/fr active Active
- 2016-03-17 AU AU2016234222A patent/AU2016234222C1/en active Active
- 2016-03-17 HU HUE16765061A patent/HUE057266T2/hu unknown
- 2016-03-17 SG SG11201707427TA patent/SG11201707427TA/en unknown
- 2016-03-17 SG SG10201907667RA patent/SG10201907667RA/en unknown
- 2016-03-17 TW TW111126713A patent/TWI778933B/zh active
- 2016-03-17 TW TW105108248A patent/TWI775723B/zh active
- 2016-03-17 CN CN201680016083.0A patent/CN107614500B/zh active Active
- 2016-03-17 PL PL16765061T patent/PL3272750T3/pl unknown
- 2016-03-17 DK DK16765061.3T patent/DK3272750T3/da active
- 2016-03-17 US US15/558,026 patent/US10442802B2/en active Active
- 2016-03-17 EP EP21203556.2A patent/EP3974430A1/fr active Pending
- 2016-03-17 BR BR112017019805-3A patent/BR112017019805B1/pt active IP Right Grant
- 2016-03-17 MY MYPI2017703345A patent/MY197742A/en unknown
- 2016-03-17 WO PCT/JP2016/058475 patent/WO2016148232A1/fr not_active Ceased
- 2016-03-17 MX MX2017011824A patent/MX384744B/es unknown
- 2016-03-17 KR KR1020237022162A patent/KR102813010B1/ko active Active
- 2016-03-17 RU RU2017134286A patent/RU2762567C2/ru active
- 2016-03-17 MA MA41790A patent/MA41790B1/fr unknown
- 2016-03-17 KR KR1020177029778A patent/KR102551969B1/ko active Active
- 2016-03-17 CN CN202110578658.0A patent/CN113292559B/zh active Active
- 2016-03-17 JP JP2017506606A patent/JP6692345B2/ja active Active
- 2016-03-17 CN CN202110577382.4A patent/CN113292558A/zh active Pending
- 2016-03-17 MX MX2021008741A patent/MX2021008741A/es unknown
-
2017
- 2017-09-11 PH PH12017501655A patent/PH12017501655B1/en unknown
- 2017-09-13 IL IL254473A patent/IL254473B/en unknown
- 2017-10-11 ZA ZA2017/06882A patent/ZA201706882B/en unknown
-
2019
- 2019-07-19 US US16/517,081 patent/US10995092B2/en active Active
-
2020
- 2020-04-10 JP JP2020071041A patent/JP2020117533A/ja not_active Ceased
- 2020-10-13 US US17/069,589 patent/US11643411B2/en active Active
- 2020-11-18 AU AU2020270503A patent/AU2020270503C9/en active Active
-
2022
- 2022-01-18 CY CY20221100041T patent/CY1124908T1/el unknown
- 2022-03-18 JP JP2022044083A patent/JP7375076B2/ja active Active
-
2023
- 2023-01-09 US US18/094,687 patent/US20230159530A1/en active Pending
- 2023-10-25 JP JP2023183221A patent/JP2024010098A/ja active Pending
-
2025
- 2025-06-10 JP JP2025096247A patent/JP2025131782A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011501A (es) | Compuestos novedosos. | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| MY197742A (en) | Morphinan derivative | |
| SV2017005384A (es) | Compuestos aminopirimidinilo | |
| MA28024A1 (fr) | Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2 | |
| MA32164B1 (fr) | Derive heterocyclique fusionne et son utilisation | |
| AR056043A1 (es) | Agonistas de receptores adrenergicos alfa2c funcionalmente selectivos | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR094272A1 (es) | Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo | |
| AR116906A1 (es) | Derivados de heteroarilo bicíclico | |
| AR116713A1 (es) | COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 | |
| MA53370B1 (fr) | Procédé et intermédiaires pour la préparation de bilastine | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| EA202192760A1 (ru) | Трициклические соединения | |
| MA50093B1 (fr) | Composé pentacyclique | |
| MA41885B1 (fr) | Mélange d'additifs | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| MX2022005415A (es) | Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo. | |
| JOP20240119A1 (ar) | مشتقات نافثيريدينون لمعالجة مرض أو اضطراب | |
| MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer |